CVKD - CIK 0001937993
The table below shows Cadrenal Therapeutics, Inc.'s cash flow statement line items across its last 4 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating cash flow | -$12.60M | -$7.36M | -$3.53M | -$1.20M |
| Capital expenditure | $5.10K | $6.54K | $3.25K | $2.28K |
| Investing cash flow | -$5.10K | -$6.54K | -$3.25K | -$2.28K |
| Dividends paid | - | - | - | - |
| Stock buybacks | - | - | - | - |
| Financing cash flow | $6.60M | $8.98M |
Cadrenal Therapeutics, Inc. reported operating cash flow of -$12.60M for fiscal year 2025. That is down 71.3% from -$7.36M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $11.90M |
| $1.24M |